FDA investigates Zolgensma after reports of cancer

The U.S. FDA opened an investigation into Novartis’ Zolgensma (onasemnogene abeparvovec) after the agency noted a “serious risk” of cancer, according to the agency’s statement. The probe follows Novartis’ disclosure about oncology cases associated with the gene therapy for spinal muscular atrophy.